Cyclophosphamide
Congenital Neutropenia
Roswell Park Cancer InstituteSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Congenital Neutropenia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Roswell Park Cancer Institute | Phase 2/3 | BB |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Fludarabine Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Anti-Thymoglobulin, Rabbit Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →